Michael A. Eldon

1.6k total citations
56 papers, 1.2k citations indexed

About

Michael A. Eldon is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Michael A. Eldon has authored 56 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Oncology. Recurrent topics in Michael A. Eldon's work include Cancer therapeutics and mechanisms (11 papers), Analytical Methods in Pharmaceuticals (10 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Michael A. Eldon is often cited by papers focused on Cancer therapeutics and mechanisms (11 papers), Analytical Methods in Pharmaceuticals (10 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Michael A. Eldon collaborates with scholars based in United States, Germany and United Kingdom. Michael A. Eldon's co-authors include Julie Bukar, John S. Patton, Alan R. Kugler, Thomas R. Browne, Ute Hoch, Mark Sostek, Allen J. Sedman, Lynn R. Webster, Jaakko Lappalainen and Barbara A. Underwood and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Michael A. Eldon

53 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael A. Eldon United States 18 339 245 213 193 174 56 1.2k
E. Marleen Kemper Netherlands 17 180 0.5× 438 1.8× 186 0.9× 548 2.8× 140 0.8× 64 1.4k
Karl Erik Giercksky Norway 23 477 1.4× 417 1.7× 56 0.3× 265 1.4× 688 4.0× 110 1.9k
Hisashi Endo Japan 16 102 0.3× 199 0.8× 104 0.5× 239 1.2× 96 0.6× 52 802
Shunsaku Nakagawa Japan 18 161 0.5× 268 1.1× 96 0.5× 304 1.6× 192 1.1× 82 1.3k
Jesper Graff Denmark 13 198 0.6× 215 0.9× 51 0.2× 94 0.5× 374 2.1× 44 1.1k
P. Stenberg Sweden 23 566 1.7× 31 0.1× 71 0.3× 217 1.1× 131 0.8× 73 1.6k
Jakob Hendel Denmark 24 150 0.4× 216 0.9× 61 0.3× 208 1.1× 626 3.6× 85 1.8k
Thomas Simon United States 23 277 0.8× 156 0.6× 40 0.2× 224 1.2× 1.3k 7.3× 46 2.7k
Warren D. Davidson United States 20 218 0.6× 66 0.3× 106 0.5× 403 2.1× 264 1.5× 61 1.4k
Gary Layton United Kingdom 22 884 2.6× 49 0.2× 87 0.4× 326 1.7× 200 1.1× 44 1.9k

Countries citing papers authored by Michael A. Eldon

Since Specialization
Citations

This map shows the geographic impact of Michael A. Eldon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Eldon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Eldon more than expected).

Fields of papers citing papers by Michael A. Eldon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Eldon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Eldon. The network helps show where Michael A. Eldon may publish in the future.

Co-authorship network of co-authors of Michael A. Eldon

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Eldon. A scholar is included among the top collaborators of Michael A. Eldon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Eldon. Michael A. Eldon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eldon, Michael A., et al.. (2020). Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 34(4). 251–261. 6 indexed citations
2.
Charych, Deborah H., Vidula Dixit, Peter Kirk, et al.. (2017). Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS ONE. 12(7). e0179431–e0179431. 111 indexed citations
3.
Adkins, Chris E., Mohamed Ismail Nounou, Afroz S. Mohammad, et al.. (2015). NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. BMC Cancer. 15(1). 685–685. 38 indexed citations
4.
Hoch, Ute, et al.. (2014). Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemotherapy and Pharmacology. 74(6). 1125–1137. 45 indexed citations
5.
6.
Staß, Heino, et al.. (2011). Pharmacokinetics and Tolerability of BAY41-6551 in Subjects with Chronic Kidney Disease. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 24(4). 191–199. 10 indexed citations
7.
Luyt, Charles‐Édouard, et al.. (2011). Pharmacokinetics and Tolerability of Amikacin Administered as BAY41-6551 Aerosol in Mechanically Ventilated Patients with Gram-Negative Pneumonia and Acute Renal Failure. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 24(4). 183–190. 27 indexed citations
8.
Eldon, Michael A., et al.. (2008). NKTR-102, a novel PEGylated-irinotecan, has a superior acute safety and tolerability profile compared to irinotecan in rats and dogs. Cancer Research. 68. 5742–5742. 2 indexed citations
9.
Eldon, Michael A., et al.. (2007). NKTR-102, a novel PEGylated irinotecan, results in sustained tumor growth suppression in mouse models of human colorectal and lung tumors that correlates with increased and sustained tumor SN38 exposure. Molecular Cancer Therapeutics. 6. 4 indexed citations
10.
Patton, John S., Julie Bukar, & Michael A. Eldon. (2004). Clinical Pharmacokinetics and Pharmacodynamics of Inhaled Insulin. Clinical Pharmacokinetics. 43(12). 781–801. 135 indexed citations
11.
12.
Boyd, Rebecca A., Bingbing Yang, Robert Abel, et al.. (1996). Pharmacokinetics of a 7‐Day 17β‐Estradiol Transdermal Delivery System: Effect of Application Site and Repeated Applications on Serum Concentrations of Estradiol and Estrone. The Journal of Clinical Pharmacology. 36(11). 998–1005. 1 indexed citations
13.
Browne, Thomas R., Alan R. Kugler, & Michael A. Eldon. (1996). Pharmacology and pharmacokinetics of fosphenytoin. Neurology. 46(6_suppl_1). S3–7. 100 indexed citations
14.
Eldon, Michael A., et al.. (1993). Effects of Oral Cimetidine or Ranitidine on the Pharmacokinetics of Intravenous Enoxacin. The Journal of Clinical Pharmacology. 33(1). 53–56. 16 indexed citations
15.
Eldon, Michael A., et al.. (1992). Clinical pharmacokinetics of procaterol: Dose proportionality after administration of single oral doses. Biopharmaceutics & Drug Disposition. 13(9). 663–669. 4 indexed citations
16.
Webb, Christine L. & Michael A. Eldon. (1991). Sensitive High-Performance Liquid Chromatographic (HPLC) Determination of Diphenhydramine in Plasma Using Fluorescence Detection. Pharmaceutical Research. 8(11). 1448–1451. 10 indexed citations
17.
Eldon, Michael A. & Wayne A. Colburn. (1990). Influence of Absorption Rate, Dosing Frequency, and Intrinsic Pharmacokinetic Profile on Steady-State Drug Concentrations. Pharmaceutical Research. 7(6). 677–680. 4 indexed citations
18.
Eldon, Michael A., et al.. (1989). Differences in Oral Verapamil Absorption as a Function of Time of Day. The Journal of Clinical Pharmacology. 29(11). 989–993. 13 indexed citations
19.
Eldon, Michael A., et al.. (1987). The Effect of Acute Withdrawal from Cigarette Smoking on Indocyanine Green and Antipyrine Clearance. The Journal of Clinical Pharmacology. 27(3). 226–232. 3 indexed citations
20.
Eldon, Michael A., et al.. (1987). Lack of Effect of Withdrawal from Cigarette Smoking on Theophylline Pharmacokinetics. The Journal of Clinical Pharmacology. 27(3). 221–225. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Marleen Kemper Breakdown of academic impact, for papers by Karl Erik Giercksky Breakdown of academic impact, for papers by Hisashi Endo Breakdown of academic impact, for papers by Shunsaku Nakagawa Breakdown of academic impact, for papers by Jesper Graff Breakdown of academic impact, for papers by P. Stenberg Breakdown of academic impact, for papers by Jakob Hendel Breakdown of academic impact, for papers by Thomas Simon Breakdown of academic impact, for papers by Warren D. Davidson Breakdown of academic impact, for papers by Gary Layton
Rankless by CCL
2026